Background {#Sec1}
==========

Proximal symphalangism is a rare genetic disorder of congenital limb malformation, characterized by ankylosis of the proximal interphalangeal joints, carpal and tarsal bone fusion, and, in some cases, conductive deafness and premature ovarian failure \[[@CR1], [@CR2]\]. The typical features of proximal symphalangism are reduced proximal interphalangeal joint space, symphalangism of the 4th and/or 5th finger \[[@CR3], [@CR4]\]. As early as in 1916, Cushing has described an American family with ankylosis of the proximal interphalangeal joints, and he named this heterozygote autosomal dominant disease as symphalangism \[[@CR5]\].

At present, there are two types of diseases in the proximal symphalangism family: (1) Proximal symphalangism-1A (SYM1A, OMIM \# 185800), which iss caused by genetic variants in *Noggin* (*NOG*) \[[@CR6], [@CR7]\]; (2) Proximal symphalangism-1B (SYM1B), which is resulted from *Growth Differentiation Factor 5* (*GDF5*) mutations \[[@CR8], [@CR9]\]. In addition, some other diseases may be also related to proximal symphalangism, such as tarsal-carpal coalition syndrome, multiple synostoses syndrome, and brachydactyly, etc. \[[@CR10], [@CR11]\].

In this study, we employed target sequencing to explore the genetic lesion of a Chinese family with symphalangism of the 4th and/or 5th finger and moderate deafness. A novel mutation (c.690C \> G/p.C230W) of *NOG* was identified in all affected individuals in this family. Furthermore, after genetic counseling and prenatal diagnosis with us, the mother successfully delivered a baby girl who did not carry the mutation.

Case presentation {#Sec2}
=================

A family from North of China (Hebei Province) with eight members across three generations participated in the study (Fig. [1](#Fig1){ref-type="fig"}a). The proband (III-2) was a 13-year-old girl with normal intelligence but symphalangism of the 4th finger in the left hand (Fig. [1](#Fig1){ref-type="fig"}b) and moderate deafness (Fig. [1](#Fig1){ref-type="fig"}c). Inner ear CT scan found abnormal inner ear structure (cochlear hypoplasia) and abnormal calcification (inner ear bone thickening and increased density) (Fig. [1](#Fig1){ref-type="fig"}d). Family history investigation found that her father (II-3) and grandmother (I-2) also suffered from hearing loss and symphalangism (Fig. [1](#Fig1){ref-type="fig"}a, e). Her grandmother has died six years ago. Her father showed the symphalangism of the 4th finger in left hand (Fig. [1](#Fig1){ref-type="fig"}e, f). He had performed the vestibulotomy and recovered the hearing one year ago. They went to the Department of Reproductive Genetics, HeBei General Hospital because the mother was pregnant with the second baby. They wanted to detect whether the second baby was normal or not. Fig. 1The Clinical data of the family. **a** The pedigree of this family. Black circles/squares are affected, white circles/squares are unaffected. N means Normal, M indicates Mutation. Arrow indicates the proband. **b** The proband showed the symphalangism of the 4th finger in the left hand. **c** Hearing testing suggests the proband suffering from moderate deafness. **d** Inner ear CT showed abnormal inner ear structure and abnormal calcification. The red circles marked the abnormal regions which indicated cochlear hypoplasia, inner ear bone thickening and increased density. **e** The symphalangism of the 4th finger in II-3. **f** Hands X-ray of III-2. The red circles marked the abnormal regions

Genetic analysis {#Sec3}
----------------

We selected the proband's genomic DNA to perform the target sequencing to detect the disease-causing mutations by Sinopath Diagnosis Company (Beijing, China). Target sequencing yielded 3.71 Gb of data with 99.088% coverage of the target region and 97.530% of the target covered over 10×. After filtering dbSNP132, 1000G, EXAC, and GenomAD database (MAF \< 0.01), only 12 mutation were left. We then conducted the co-segregation analysis by Sanger sequencing and only seven variants were exist in affected individuals and were absent in healthy members (Table [1](#Tab1){ref-type="table"}). We further performed the bioinformatics analysis including MutationTaster, SIFT, Polyphen-2, PANTHER, ToppGene function analysis, OMIM clinical phenotype analysis and ACMG classification (Table [1](#Tab1){ref-type="table"}), we highly suspected the novel mutation (c.690C \> G/p.C230W) of *NOG,* belonging to PM1 and PM2 in ACMG guidelines \[[@CR12]\], was responsible for the family with SMY1A. This mutation resulted in a substitution of in polar amino acid cysteine by nonpolar amino acid tryptophan in the codon 230 of exon 1 of *NOG* gene, and was not presented in our 200 control cohorts. Noggin amino acid sequence alignment analysis suggested that this mutation was located in a highly evolutionarily conserved site (Fig. [2](#Fig2){ref-type="fig"}b). In addition, we also constructed a part model of the Noggin protein using SWISS-MODEL (<https://swissmodel.expasy.org>) (Fig. [2](#Fig2){ref-type="fig"}c) and, after applying SDM software (<http://marid.bioc.cam.ac.uk/sdm2/prediction>) to analyze the structure, it was found that this novel mutation might increase the solvent accessibility (WT:16.9% and Mutant: 39.9%) and reduce the stability of the Noggin protein. Table 1The mutations list after data filtering and co-segregation analysisCHRPOSRBABGeneMutationSIFTPolyPhen-2MutationTasterPANTHEROMIM clinical phenotypeToppGene functionACMG classification145,481,060CT*UROD*NM_000374: c.994C \> T, p.R332C0,D0.94,D0.99,D--AD or AR: Porphyria cutanea tardaheme biosynthetic processBP52149,216,410GA*MBD5*NM_018328: c.83G \> A, p.R28H0,D0.99,D0.99,DPAD: Mental retardationresponse to growth hormoneBP52189,953,479GT*COL5A2*NM_000393: c.587G \> T, p.A196D0.29,T0.98,D0.99,D--AD: Ehlers-Danlos syndromeregulation of endodermal cell differentiationBP4, BP5338,674,642GA*SCN5A*NM_198056: 157G \> A, p.R53W0,D0.36,B0.95,DPAD: Atrial fibrillationvoltage-gated sodium channel activityBP4, BP53184,953,112GA*EHHADH*NM_001966: c.317G \> A, p.A106V0,D0.99,D0.99,DPAD: Fanconi renotubular syndromeperoxisomal transportBP51748,701,856GACACNA1GNM_018896: c.6365G \> A, p.R2122H0.04,D0.01,B0.8,DPAD: Spinocerebellar ataxiavoltage-gated calcium channelBP4, BP51754,672,274CG*NOG*NM_005450: c.690C \> G, p.C230W0,D0.99,D0.99,DDAD: Symphalangism proximalfibroblast growth factor receptor signaling pathwayPM1, PM2*CHR* Chromosome, *POS* position, *RB* reference sequence base, *AB* alternative base identified, *D* damaging, *P* probably damaging, *B* Benign, *T* Tolerated, *AR* autosomal recessive, *AD* autosomal dominant, *BP* Benign Supporting, *PM* Pathogenicity Moderate Fig. 2Genetic analysis of the family. **a** Sanger DNA sequencing chromatogram demonstrates the heterozygosity for a *NOG* mutation (c.690C \> G/p.C230W). **b** Analysis of the mutation and protein domains of Noggin. The C230 affected amino acid locates in the highly conserved amino acid region in different mammals (from Ensembl). The black arrow and red words show the C230 site. **c** Swiss-model analyzed the Noggin structures of WT and Mutated (p.C230W). **d** The healthy hands of III-3 and normal sequences of amniotic fluid DNA

Prenatal diagnosis {#Sec4}
------------------

When the parents came to our hospital, the mother has been pregnant with the second baby for 17 weeks and they wanted to have a healthy baby. According to ACMG classification, the novel mutation (c.690C \> G/p.C230W) of *NOG* belongs to PM1 and PM2. Simultaneously, target sequencing only identified this mutation as a pathogenic variant. So, we highly believed the novel mutation (c.690C \> G/p.C230W) of *NOG* was the genetic lesion of the family with proximal symphalangism and hearing loss. We then performed the Sanger sequencing of amniotic fluid DNA to detect the mutation, fortunately, the results showed a normal allele of the second baby. And 22 weeks later, the mother delivered a 3.4-kg healthy girl (Fig. [2](#Fig2){ref-type="fig"}d).

Discussion {#Sec5}
==========

The human *NOG* gene encoding Noggin protein is located on chromosome 17q22, and it consists of one exon, spanning approximately 1.9 kilobases (kb) \[[@CR6]\]. Noggin protein is involved in the development of many body tissues, including nerve tissue, muscles, and bones and the role of Noggin in bone development makes it significant for proper joint formation \[[@CR13]\]. According to previous researches, Noggin protein can interact with bone morphogenetic proteins (BMPs) and regulate the development of bone and other tissues \[[@CR14]\]. In detail, the Noggin protein regulates the activity of BMPs by binding to them and blocking them from attaching to the downstream receptor, which results in a decrease in BMP signaling \[[@CR15]\]. In our research, the novel mutation (c.690C \> G/p.C230W) of *NOG* can increase the solvent accessibility and reduce the stability of the Noggin, which may active the BMP signal pathway and lead to bone diseases.

In 1999, five *NOG* mutations were identified in unrelated families with symphalangism (SYM1A) and a de novo mutation in a patient with unaffected parents \[[@CR6]\]. Interestingly, a wide variety of bone development anomalies, including tarsal/carpal coalition syndrome \[[@CR10]\], brachydactyly \[[@CR16]\], multiple synostoses syndrome \[[@CR17]\], Stapes ankylosis with broad thumbs and toes \[[@CR18]\], have been reported in patients with *NOG* mutations. Similar observations were also reported in the families even with the same mutation \[[@CR16], [@CR19]\]. Therefore, the pleiotropic types of bone diseases and significant genetic heterogeneity make it difficult to be diagnosed. We summarized the previous reports and found that approximately 57 mutations (60 patients) of *NOG* have been identified in different types of disorders (Table [2](#Tab2){ref-type="table"}). Table 2The summary of reported mutations of NOGNo.MutationPhenotypesReference**1p. Leu20fsMultiple synostoses syndromeTakahashi et al. (2001)**2p. Pro35AlaBrachydactyly type BLehmann et al. (2007)**3p. Pro35SerTeunissen-Cremers syndromeHirshoren et al. (2008)4p. Pro35SerProximal symphalangismMangino et al. (2002)**5p. Pro35SerBrachydactyly type BLehmann et al. (2007)6p. Pro35ArgProximal symphalangismGong et al. (1999)7p. Pro35ArgTarsal--carpal coalition syndromeDixon et at. (2001)8p. Ala36ProBrachydactyly type BLehmann et al. (2007)**9p. Pro37ArgTarsal--carpal coalition syndromeDebeer et al. (2004)**10p. Pro42AlaMultiple synostoses syndromeDebeer et al. (2005)11p. Pro42SerProximal symphalangismSha et al. (2019)12p. Pro42ArgMultiple synostoses syndromeOxley et al. (2008)13p. Pro42ThrMultiple synostoses syndromeAydin, H et al. (2013)**14p. Val44fsTeunissen-Cremers syndromeWeekamp et al. (2005)**15p. Glu48LysBrachydactyly type BLehmann et al. (2007)**16p. Glu48LysProximal symphalangismKosaki et al. (2004)**17p. Pro50ArgTarsal--carpal coalition syndromeDebeer et al. (2005)18p. Asp55TyrProximal symphalangismXiong et al. (2019)**19p. Glu85fsStapes ankylosis with broad thumb and toesBrown et al. (2002)**20p. Arg87fsMultiple synostoses syndromeLee et al. (2014)21p. Gly91CysFibrodysplasia ossificans progressivaKaplan et al. (2008)22p. Gly92ArgFibrodysplasia ossificans progressivaKaplan et al. (2008)23p. Gly92GluFibrodysplasia ossificans progressivaKaplan et al. (2008)24p. Ala95ThrFibrodysplasia ossificans progressivaKaplan et al. (2008)**25p. Ala102fsProximal symphalangismThomeer et al. (2011)26p. Gln110XStapes ankylosis with broad thumb and toesBrown et al. (2002)27p. Leu129XProximal symphalangismTakahashi et al. (2001)28p.Gln131XStapes ankylosis with broad thumbs and toesTakashi etal. (2014)29p. Lys133XStapes ankylosis with broad thumb and toesTakano et al. (2016)30p. Arg136CysProximal symphalangismMasuda et al. (2014)31p. Trp150CysProximal symphalangismPan et al. (2015)32p. Cys155PheStapes ankylosis with symphalangismUsami et al. (2012)**33p. Cys155SerProximal symphalangismUsami et al. (2012)34p. Arg167GlyBrachydactyly type BLehmann et al. (2007)35p. Arg167CysProximal symphalangismLiu et al. (2015)36p. Cys184TyrProximal symphalangismTakahashi et al. 2001**37p. Cys184PheProximal symphalangismUsami et al. 2012**38p. Pro187SerBrachydactyly type BLehmann et al. (2007)**39p. Pro187AlaProximal symphalangismGanaha et al. (2015)40p. Glu188fsTeunissen-Cremers syndromeWeekamp et al. (2005)**41p. Gly189CysProximal symphalangismGong et al. (1999)**42p. Met190ValMultiple synostoses syndromeOxley et al. (2008)43p. Leu203ProTeunissen-Cremers syndromeWeekamp et al. (2005)44p. Arg204LeuTarsal/carpal coalition syndromeDixon et al. (2001)**45p. Arg204GlnTarsal-carpal coalition syndromeDas et al. (2018)46p. Trp205XMultiple synostoses syndromeDawson et al. (2006)**47p. Trp205CysFacioaudiosymphalangism syndromevan den Ende et al. (2005)**48p. Trp205fsStapes ankylosis with broad thumb and toesEmery et al. (2009)**49p. Cys215XStapes ankylosis with broad thumb and toesUsami et al. (2012)**50p. Trp217GlyMultiple synostoses syndromeGong et al. (1999)**51p. Ile220AsnProximal symphalangismGong et al. (1999)52p. Ile220fsProximal symphalangismGong et al. (1999)**53p. Tyr222AspProximal symphalangismGong et al. (1999)54p. Tyr222CysProximal symphalangismGong et al. (1999)55p. Tyr222CysTarsal--carpal coalition syndromeDixon et al. (2001)56p. Pro223LeuProximal symphalangismGong et al. (1999)**57p. Cys228GlyStapes ankylosis with broad thumb and toesIshino et al. (2015)58p. Cys228AlaMultiple synostoses syndromeGanaha et al. (2015)59p. Cys230TyrMultiple synostoses syndromeBayat et al. (2016)60p. Cys230TrpProximal symphalangismPresent study61p. Cys232TrpMultiple synostoses syndromeRudnik-Schöneborn et al. (2010)**Bold words indicate the patients with deafness

In this study, a family with symphalangism and moderate deafness was investigated by target sequencing. Genetic analysis found a novel mutation (c.690C \> G/p.C230W) of *NOG* in two affected members. Of note, both of two patients with p.C230W in the family were associated with hearing loss. To date, 29 mutations have been reported in symphalangism patients related to deafness (Table [2](#Tab2){ref-type="table"}) \[[@CR11]\]. And the mutation p.C230W was the fifth report related to *NOG* mutation, although some Chinese journals have also published some reported mutations. Meanwhile, this difference also suggested that there were still a lot of novel mutations need to discovery in Chinese population.

The p.C230W mutation disrupts the cysteine knot motif of the C-terminal domain of Noggin (amino acids 155--232), which contains a series of nine cysteine residues and was shown to target the molecule to a specific receptor protein \[[@CR20], [@CR21]\]. The similar mutations (p.C228G, p.C228S, p.C230Y and p.C232W) have been identified in patients with symphalangism and hearing loss, which indicated that mutations in cysteine residues may be related to abnormal development of auditory ossicles and hearing loss \[[@CR19], [@CR22]--[@CR24]\].

In clinical genetics, the aim of mutation detection is to make contributions to genetic diagnosis and counseling. In this study, we identified the genetic lesion of the family by target sequencing. All the filtered data were shown in Table [1](#Tab1){ref-type="table"}. We not only performed the informatics analysis of the novel mutation by multi-different algorithm based bioinformatics programs, but also followed the ACMG guidelines to estimate the pathogenicity of the novel mutation strictly (PM1 and PM2). Finally, we highly believed that the novel mutation (p.C230W) of *NOG* may be the genetic lesion of the family. We then assisted the family to get a healthy baby by amniotic fluid DNA sequencing referring to other people's research \[[@CR25]\]. Prenatal diagnosis not only helped the patient to delivery healthy baby and improved the population quality but also relieved psychological and financial stress \[[@CR26]\]. Our study provided a successful example for genetic counseling and prenatal diagnosis of patients with SYM1A.

Conclusions {#Sec6}
===========

We reported a novel *NOG* mutation (c.690C \> G/p.C230W) in a three-generation family with SYM1A. And we helped them delivery a girl baby who did not carry the mutation by genetic counseling and prenatal diagnosis. Our study not only presented the important role of *NOG* in proximal symphalangism and deafness but also expanded the spectrum of *NOG* mutations and contributed to genetic diagnosis and counseling of families with SYM1A.
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